Under this agreement, Scil Technology is primarily responsible for all R&D activities with Medtronic responsible for clinical trials, regulatory approvals and commercialization.
These regenerative biologics may offer new approaches to saving teeth in patients who are at risk for tooth loss due to periodontal disease and provide new options for other dental procedures for the placement of dental implants. These therapies would be alternative treatments to the traditional bridging procedures performed by dentists.
Pete Wehrly, senior vice president and president of Medtronic’s spinal and biologics business, said: “The partnership with Scil is a continuation of our strategy to expand our biologics portfolio. Scil’s therapies have the potential to offer our customers biologic solutions that will expand treatment options for their patients and offer new options for unmet needs in periodontal regeneration.”